Story maps
故事地圖



(added on 2015/11/30)

Dual protection 雙重保護

©2015 SpatioEpi.com
Data source: UNAIDS, World Bank and published scientific literatures
Map created by CUHK SpatioEpi Group

Enlarge   Back


Antiretroviral medicines can be used for preventing HIV infection, a new measure referred as ‘prophylaxis’. The map shows the distribution of countries where pilot studies on “Pre-exposure Prophylaxis” (PrEP) for men who have sex with men (MSM) are conducted, as of October 2015. A total of 27 studies are conducted in 14 countries, which are located mainly in Europe and the Americas. In Asia, the only participating country is Thailand.

Before PrEP is prescribed, a negative HIV antibody test result is required. The HIV testing rate among MSM in these countries varied, ranging from 7% to 67%. A higher testing rate may result in a higher number of eligible MSM who can be identified. The community risk of transmission could be minimized if all HIV -ve MSM take PrEP and practise safer sex.

As PrEP involves the prescription of antiretroviral medicine, its access at country level is crucial. Most of the countries on the map have a relatively high coverage of HIV treatment for infected patients, implying that their regularization of a PrEP programme is possible after pilot studies.

Data for the map were retrieved from websites of UNAIDS, World Bank and published scientific literatures.

處方抗病毒藥物是一種新的預防愛滋病毒感染方法。地圖顯示全球參與男同性接觸者『暴露前預防性投藥』先導性研究的國家分佈。2015年10月的資料顯示,十四個國家共參與二十七項研究。這些研究大部份在歐洲及美洲,而亞洲唯一的參與國為泰國。

『暴露前預防性投藥』的目標群眾是沒有感染愛滋病毒的人士。抗體測試率反映社群中得悉自己有否感染的人數。參與研究各國的測試率都不盡相同,而大部份國家男同性接觸者的測試率都較高,顯示適合參加的人數不少。若社群中所有沒有感染的人士都進行安全性行為及服用預防性投藥,感染風險便可大大降低。

此外,由於『暴露前預防性投藥』涉及處方抗病毒藥物,故此藥物的可及性亦是計劃開展的重要一環。地圖中部份國家的愛滋病毒感染者治療覆蓋率都頗高,反映先導性研究結束後,預防性投藥的將可望普及化。

地圖數據源自聯合國愛滋病規劃署、世界銀行及已刊載文獻。